Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University

Krakow, Poland, October 7, 2021 – Ryvu Therapeutics (WSE:RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, co-runs the fourth edition of Drug Discovery and Development MSc degree at the Faculty of Pharmacy, Jagiellonian University.

The Drug Discovery and Development programme is focused on all aspects of identifying and introducing new medicines. Its mission is to deliver high-level specialists equipped with a highly applied scientific basis for discovering and developing novel pharmacotherapeutics, combined with focused, real-life practical skills. Graduates of DDD will learn how new medicines are sought, identified, developed, manufactured and tested, along with the most important aspects of regulatory processes necessary for their formal approval as drug products. Additionally, they will be equipped with management skills and language expertise, supporting their future employment in the worldwide pharma-biotech industry, regulatory agencies or drug research centres.

This degree provides a solid grounding in pharmaceutical sciences, together with an opportunity to specialize in particular drug discovery and development areas. As a partner of Jagiellonian University, Ryvu Therapeutics funds awards for the best master’s thesis, organizes the internship programme for students, and leads some of the classes.

Read more about the Drug Discovery and Development Jagiellonian University programme at https://ddd.farmacja.cm.uj.edu.pl/